Healthcare professionals
On this page, you will find information on the European Medicines Agency’s (EMA) activities that are most relevant to healthcare professionals, including news and events.
French is available via eTranslation, the European Commission's machine translation service.
Translate to French | Important information about machine translation
You can contribute to EMA's work by responding to our public consultations.
Learn more about how healthcare professionals are actively involved in EMA's work.
Featured information for healthcare professionals
EMA chairing One Health task force
In 2026, EMA is chairing a cross-agency task force implementing the One Health approach in Europe. One Health aims to enable the EU and its Member States to better prevent, predict, detect and respond to health threats.
Report on EMA-HMA medicine repurposing pilot
A report is available on a pilot that provided tailored scientific advice to not-for-profit organisations and academics on repurposing authorised medicines for new indications. The report contains findings and recommendations from the pilot. EMA and Heads of Medicines Agencies (HMA) carried out this pilot between 2021 and 2024.
EMA communication activities: 2024 survey results
We asked stakeholders for feedback on our external communication activities via a bi-annual survey disseminated in May 2024. The results are available in a newly-published report. They help us to establish baselines and targets to measure progress, analyse trends and address areas for improvement.
Guidance on medicine shortages
Guidance is available on the actions that patients and healthcare professionals can take to help prevent and manage shortages of human medicines in the EU. An infosheet and infocards are also available to summarise the recommendations in the guidance.
Questions and answers on interchangeability of biosimilars
A 'questions and answers' document is available for healthcare professionals, patients and other stakeholders to further address issues related to the interchangeability of biosimilars in EU countries. This complements the information that EMA and the Heads of Medicines Agencies provided in a joint statement on this topic, in September 2022.
European medicines agencies network strategy to 2028
The strategy sets out how the network will continue to enable the supply of safe and effective medicines, in the face of developments in science, medicine, digital technologies, globalisation and emerging health threats, such as the COVID-19 pandemic.
Latest news
Image credit: © tadamichi | stock.adobe.com
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 6-9 July 2026
PRAC agrees new safety information on desogestrel- and etonogestrel-containing contraceptives and Litfulo, a medicine to treat alopecia areata
Image credit: © Chinnapong | stock.adobe.com
EMA fast tracks review of a medicine for metastatic pancreatic cancer
Phased review has started to accelerate assessment of medicine with potential to address high unmet medical need
Image credit: © Sabrina | stock.adobe.com
EMA steps up efforts on medicines for women’s health
Initiatives to map gaps, challenges and prioritise further actions
EMA recommends revoking marketing authorisation for Tavneos
Benefits no longer proven to outweigh risks of treatment
Publications of interest
Video: Working for every patient in Europe
Watch our short video for a quick and easy explanation of who EMA is and what it does. (video in English, with subtitles in 24 different languages).
Video: 25 years of EMA engagement with patients and healthcare professionals
Watch our short video to see how our interactions with patients and healthcare professionals have evolved over the last 25 years (video in English).
EMA's 2023 annual report
Navigate through the digital report to view interviews, short videos and an interactive timeline of the Agency’s main activities in 2023. Read the traditional PDF version to see additional figures and statistics on EMA's regulatory procedures and activities.